Latest Breaking News On - Debasish roychowdhury - Page 1 : vimarsana.com
Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
FX-06 is a synthetic peptide with a broad spectrum of potential applications associated with endothelial barrier integrity, blood vessel permeability and inflammation
Potential applications include COVID-19, pandemic, chemical, biological, radiological and nuclear threats
News provided by
Share this article
Share this article
LEXINGTON, Mass., March 3, 2021 /PRNewswire/ Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications. The partnership will focus on exploring potential collaborations with the U.S. Government to develop FX-06 as a medical countermeasure against high priority threats for which there are s
Germany
Austria
Wellington
New-zealand-general
New-zealand
Vienna
Wien
Munich
Bayern
Austrian
John-mcmanus
Anne-burger